Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
Chiara Lupi,1 Simona Guerzoni,2 Andrea Negro,3 Silvia Benemei1 1Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 2Medical Toxicology Unit, Headache and Drug Abuse Centre, Department of Biomedical, Metabolic and Neural Sciences, Un...
Main Authors: | Lupi C, Guerzoni S, Negro A, Benemei S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-04-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/once-monthly-galcanezumab-for-the-prevention-of-migraine-in-adults-an--peer-reviewed-article-TCRM |
Similar Items
-
Reducing Episodic Cluster Headaches: Focus on Galcanezumab
by: Pellesi L, et al.
Published: (2020-07-01) -
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
by: Stauffer VL, et al.
Published: (2018-09-01) -
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
by: Fabrizio Vernieri, et al.
Published: (2021-05-01) -
Fremanezumab in the treatment of migraines: evidence to date
by: Robblee J, et al.
Published: (2019-08-01) -
An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)